Mechanical ‘endermologie’ device said to curb cravings and slim legs after 12 sessions, user reports

A non‑invasive mechanical massage device marketed as a body‑contouring treatment is being promoted by its manufacturer as capable of reducing appetite and improving body shape after a 12‑session programme, and a user who completed the course in London reported marked changes in cravings, water retention and physical energy.

The device, the Cellu M6 Infinity from LPG, uses motorised rollers and suction to stimulate tissue and lymphatic drainage. The manufacturer cites clinical trials it says show a 4.3 percent increase in leptin, an appetite‑suppressing hormone, and reports improved eating behaviour after a 12‑session course. The company also emphasises that it does not position the technology as an alternative to prescription weight‑loss drugs.

A reporter who undertook a customised 12‑session Body Contouring Programme at the company’s West London clinic described the sessions as deeply relaxing and said she experienced reductions in long‑standing water retention in her legs, visibly smoother skin and a decrease in cellulite by the eighth treatment. She reported feeling lighter by the second appointment, sleeping during many sessions and leaving appointments with increased energy and a greater inclination to walk; by the end of the course she said her daily step count rose to about 20,000.

The treatment is administered while clients wear a full‑body stocking. The motorised head does not directly contact the skin and applies suction and rolling movements that the company says provide deeper cellular stimulation than manual massage and promote lymphatic drainage. The clinic’s recommended schedule for optimal results is twice weekly for the 12 sessions, though the reporter’s appointments were more spread out for logistical reasons.

Alongside physical changes, the user reported a marked reduction in cravings for sugary and salty foods and said she was feeling full faster after meals. The manufacturer attributes appetite changes to hormonal shifts observed in the trials; it has also cited independent studies reporting reductions in cortisol after similar mechanical treatments, and noted that lower cortisol levels can influence appetite‑regulating hormones such as leptin.

The company’s pricing for clinic sessions was reported at about £120 for an hour and it recommended monthly maintenance treatments to sustain benefits. Promotional material notes per‑minute rates for some offerings and the manufacturer’s website lists further program details.

The treatment traces its origins to physiotherapy and has been used for decades in some European markets. Advocates say it can aid lymphatic drainage, reduce fluid retention and improve the texture of skin; the maker of the Cellu M6 Infinity says the latest generation adds software and tissue analysis to personalise treatment settings.

The manufacturer’s trial data are presented in company literature and have been referenced in promotional materials. While some academic and clinical papers have explored mechanical massage and lymphatic stimulation, independent assessments of the device’s longer‑term effects on weight and appetite hormones remain limited in scale and scope. The company explicitly states its device is not a replacement for prescription medications used to treat obesity.

The reporter compared the per‑session cost with prescription GLP‑1 medicines commonly used for weight loss, noting that monthly costs for some injectable drugs have risen and can exceed the clinic’s per‑session rate. She said she had not ruled out injectable medications but that, following the course, she did not feel they were necessary for the short term.

Clinicians and public‑health authorities typically advise that weight‑management strategies combine medical assessment, behavioural support, nutrition and physical activity. Non‑invasive therapies aimed at body contouring and lymphatic drainage are used by some patients for cosmetic and symptomatic relief of fluid retention, but experts caution that claims about appetite suppression and hormonal changes should be evaluated through larger, independent clinical trials.

The user said maintenance would be required to preserve benefits and described the experience as drug‑free and needle‑free, concluding that the programme had produced tangible changes in appetite, body shape and energy levels after completing the 12 sessions.